Cetera Investment Advisers acquired a new position in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 37,163 shares of the company's stock, valued at approximately $1,020,000.
Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Norges Bank acquired a new stake in BridgeBio Pharma during the fourth quarter valued at $29,237,000. Alyeska Investment Group L.P. acquired a new position in BridgeBio Pharma in the 4th quarter valued at $25,805,000. Capital Research Global Investors lifted its position in shares of BridgeBio Pharma by 34.9% during the 4th quarter. Capital Research Global Investors now owns 3,526,747 shares of the company's stock worth $96,774,000 after purchasing an additional 912,439 shares during the last quarter. Vanguard Group Inc. boosted its position in shares of BridgeBio Pharma by 6.2% in the fourth quarter. Vanguard Group Inc. now owns 15,077,915 shares of the company's stock valued at $413,738,000 after acquiring an additional 879,059 shares during the period. Finally, The Manufacturers Life Insurance Company grew its position in BridgeBio Pharma by 23.1% in the 4th quarter. The Manufacturers Life Insurance Company now owns 1,885,794 shares of the company's stock worth $51,746,000 after purchasing an additional 353,570 shares during the last quarter. 99.85% of the stock is currently owned by hedge funds and other institutional investors.
BridgeBio Pharma Trading Up 3.4%
Shares of BridgeBio Pharma stock traded up $1.11 during trading hours on Thursday, reaching $33.37. 2,623,253 shares of the company's stock were exchanged, compared to its average volume of 2,444,886. The stock has a market cap of $6.34 billion, a P/E ratio of -11.71 and a beta of 1.15. The company has a 50 day moving average of $34.35 and a two-hundred day moving average of $32.02. BridgeBio Pharma, Inc. has a fifty-two week low of $21.62 and a fifty-two week high of $39.54.
BridgeBio Pharma (NASDAQ:BBIO - Get Free Report) last released its earnings results on Tuesday, April 29th. The company reported ($0.88) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.00) by $0.12. The company had revenue of $36.74 million for the quarter, compared to the consensus estimate of $57.14 million. The business's revenue was down 44.8% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.20) EPS. As a group, analysts expect that BridgeBio Pharma, Inc. will post -3.67 earnings per share for the current fiscal year.
Insider Buying and Selling
In other news, Director Andrea Ellis sold 30,000 shares of the business's stock in a transaction that occurred on Tuesday, April 1st. The stock was sold at an average price of $34.05, for a total transaction of $1,021,500.00. Following the completion of the sale, the director now owns 12,000 shares in the company, valued at $408,600. The trade was a 71.43% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, major shareholder Genetic Disorder L.P. Kkr sold 6,000,000 shares of the company's stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $32.96, for a total value of $197,760,000.00. Following the completion of the transaction, the insider now directly owns 19,260,971 shares in the company, valued at $634,841,604.16. The trade was a 23.75% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 12,392,182 shares of company stock worth $416,921,291. Insiders own 18.20% of the company's stock.
Analysts Set New Price Targets
A number of research firms have weighed in on BBIO. HC Wainwright lifted their price target on shares of BridgeBio Pharma from $49.00 to $53.00 and gave the stock a "buy" rating in a research note on Tuesday, April 15th. UBS Group boosted their target price on shares of BridgeBio Pharma from $65.00 to $72.00 and gave the stock a "buy" rating in a research note on Wednesday, April 30th. Scotiabank upped their price target on BridgeBio Pharma from $52.00 to $55.00 and gave the company a "sector outperform" rating in a research note on Wednesday, April 30th. JPMorgan Chase & Co. lifted their target price on shares of BridgeBio Pharma from $44.00 to $50.00 and gave the stock an "overweight" rating in a report on Monday, March 24th. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $95.00 price target on shares of BridgeBio Pharma in a research note on Friday, February 21st. One analyst has rated the stock with a hold rating and eleven have issued a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $57.09.
Check Out Our Latest Analysis on BBIO
BridgeBio Pharma Company Profile
(
Free Report)
BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.
See Also

Before you consider BridgeBio Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BridgeBio Pharma wasn't on the list.
While BridgeBio Pharma currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report